Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Semin Hematol. 2011 Jul;48(3):172-84. doi: 10.1053/j.seminhematol.2011.05.002.
The prognostic impact of minimal residual disease (MRD) has been demonstrated for several hematologic malignancies. While in acute lymphoblastic leukemias MRD assessment by polymerase chain reaction (PCR)-based methods has been established as an important tool for clinical risk assessment and is part of clinical management, data demonstrating a prognostic value of MRD in mantle cell lymphoma (MCL) were sparse and results from randomized trials have been published only recently. In the present review technical aspects of different MRD detection methods are discussed, as well as the prognostic relevance of MRD in the context of clinical trials in patients with MCL. Furthermore, recommendations are given for workflow and useful implication of MRD in future clinical trials design.
微小残留病灶（MRD）的预后影响已在多种血液恶性肿瘤中得到证实。虽然在急性淋巴细胞白血病中，基于聚合酶链反应（PCR）的方法评估 MRD 已被确立为临床风险评估的重要工具，也是临床管理的一部分，但在套细胞淋巴瘤（MCL）中，MRD 具有预后价值的数据很少，并且最近才发表了随机试验的结果。在本综述中，讨论了不同 MRD 检测方法的技术方面，以及 MCL 患者临床试验中 MRD 的预后相关性。此外，还为未来临床试验设计中 MRD 的工作流程和有用性提供了建议。
